Updated Jul 16, 2026
Doyle John Brendan has filed 2 SEC Form 4 filings across 1 company in the last 90 days — buying. Lifetime open-market purchases: $11K.

John Brendan Doyle is the Chief Financial Officer of Cognition Therapeutics Inc, a clinical-stage biopharmaceutical company focused on developing therapeutics for age-related diseases. He has been involved in the company's financial operations and strategic planning.
| Role | Chief Financial Officer |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-04 | CGTX | COGNITION THERAPEUTICS INC | F — Tax withholding / forfeiture | 8.6K | $1.28 | $11K |
| 2026-04-20 | CGTX | COGNITION THERAPEUTICS INC | P — Open-market purchase | 10.0K | $1.13 | $11K |
| 2026-02-18 | CGTX | COGNITION THERAPEUTICS INC | F — Tax withholding / forfeiture | 1.6K | $1.12 | $2K |
| 2026-02-05 | CGTX | COGNITION THERAPEUTICS INC | F — Tax withholding / forfeiture | 26.9K | $1.03 | $28K |
| 2026-02-05 | CGTX | COGNITION THERAPEUTICS INC | A — Grant or award | 200.0K | $0.00 | |
| 2025-07-29 | CGTX | COGNITION THERAPEUTICS INC | F — Tax withholding / forfeiture | 9.4K | $0.67 | $6K |
| 2025-07-29 | CGTX | COGNITION THERAPEUTICS INC | A — Grant or award | 30.0K | $0.00 |
John Brendan Doyle is the Chief Financial Officer of Cognition Therapeutics Inc, a clinical-stage biopharmaceutical company focused on developing therapeutics for age-related diseases. He has been involved in the company's financial operations and strategic planning.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($11K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Doyle John Brendan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.